Clinical Issues in Atopic Dermatitis

Dinner will be provided.

There is no registration fee for attending this program; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.

This activity is provided by Integritas Communications. 

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

This program is independent and is not part of the official AAD Summer Meeting, as planned by its Scientific Assembly Committee.

This live activity will not offer continuing medical education (CME) credit.

Target Audience

The educational design of this activity addresses the needs of dermatologists, allergists/clinical immunologists, and other clinicians who treat patients with severe atopic dermatitis.

Program Agenda

6:30 PM – 7:00 PM  Registration and Dinner
7:00 PM – 7:20 PM  Introduction to Atopic Dermatitis Pathophysiology
7:20 PM – 7:55 PM  Comprehensive Patient Evaluations: From Triggers to Comorbidities
7:55 PM – 8:30 PM  Individualizing Long-term Therapy for Patients With Moderate-to-Severe Atopic Dermatitis
8:30 PM – 8:45 PM  Choose-a-Case: Case Study Discussion
8:45 PM – 9:00 PM  Question and Answer Session

Statement of Need/Program Overview

Atopic dermatitis is a common, chronic, inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.^1,2 The disease-related physical and biopsychosocial burdens of this condition can have a substantial effect on patient and parent/caregiver quality of life.^3,4 A better understanding of disease etiology has supported the development of new approaches to disease characterization and targeted therapies.^5,6 As a result, the first biologic therapy is now FDA-approved to treat adolescent and adult patients 12 years and older, with moderate-to-severe disease.^7,8 In this Clinical Issues™ program, an expert faculty panel will discuss and debate the pathophysiologic underpinnings of atopic dermatitis, considerations related to comprehensively evaluating patients, and recommended therapeutic strategies for adolescents and adults with moderate-to-severe disease. With novel therapies emerging for patients with difficult-to-treat atopic dermatitis, attendees will benefit from updates on the newest clinical trial data, evolving treatment guidelines, and practical recommendations that may be applied to daily clinical decision-making^.9,10 Attendees will leave this dynamic and engaging program well-equipped to translate the latest information and new perspectives on disease management into next-day practice.

References

1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015:66(suppl 1):8-16.
2. Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
3. Carroll CL, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192-199.
4. Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
5. Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
6. Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
7. Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
8. Simpson EL, et al. Dupilumab efficacy and safety in adolescents with moderate-to-severe atopic dermatitis: results from a multicenter, randomized, placebo-controlled, double-blind, parallel-group, phase 3 study. Presented at the 27th EADV Congress. September 12-16, 2018, Paris, France. Poster #4640.
9. Renert-Yuval Y, Guttman-Yassky E. What’s New in Atopic Dermatitis. Dermatol Clin. 2019;37(2):205-213.
10. Ariëns LFM, et al. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis. 2018;9(9):159-170.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

• Describe the pathophysiologic mechanisms and risk factors that contribute to atopic dermatitis development and persistence, with a focus on specific targets of current and emerging systemic treatments
• Assess patients with atopic dermatitis over time for uncontrolled symptoms, sleep disturbances, comorbid conditions, and treatment responses
• Describe the mechanistic rationales and clinical evidence for current and emerging biologic therapies in the treatment of moderate-to-severe atopic dermatitis
• Individualize long-term therapeutic regimens for moderate-to-severe atopic dermatitis to prevent exacerbations, manage comorbidities, maximize health-related quality of life, and minimize treatment-related side effects
• Communicate with patients and caregivers to improve their understanding of atopic dermatitis and the importance of treatment adherence and to promote shared decision-making

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Nora Eldasher prior to the live event at neldasher@integritasgrp.com.